INCREASED RIBAVIRIN BIOAVAILABILITY ASSOCIATED WITH TELAPREVIR USE IN HEPATITIS C PATIENTS TREATED WITH PEGYLATED -INTERFERON/RIBAVIRIN/TELAPREVIR TRIPLE THERAPY

Q: How can I download an article?

To download an article from SID, first log in to the site, search for the article title, and click on the 'Download Article' option.

Q: How can I download an ISI article?

To download an ISI article on SID, enter the keyword or article title in the search bar, view the relevant results, click on the desired article, and select the 'Download Article' option.

Q: How can I access the SID database?

To access the SID database, visit SID.ir, create an account, and log in to access scientific resources.

Q: Is downloading articles from SID free?

Some articles on SID are available for free, while others require payment. Details are specified on the article's page.

PRADAT PIERRE; VIRLOGEUX VICTOR; MAYNARD MARIANNE; LECLERCQ MATHILDE; HATU GIORGIANA; AMIRI MAJID; LEBOSSE FANNY; MIAILHES PATRICK; ZOULIM FABIEN; GAGNIEU MARIE CLAUDE; BAILLY FRANCOIS

مرکز اطلاعات علمی Scientific Information Database (SID) - Trusted Source for Research and Academic Resources

Journal Paper

Paper Information

Journal: Hepatitis Monthly Year:2015 | Volume:15 | Issue:9 Page(s): 0-0

Download Full-Text

View:

311

Download:

160

Cites:

Information Journal Paper

Title

INCREASED RIBAVIRIN BIOAVAILABILITY ASSOCIATED WITH TELAPREVIR USE IN HEPATITIS C PATIENTS TREATED WITH PEGYLATED -INTERFERON/RIBAVIRIN/TELAPREVIR TRIPLE THERAPY

Author(s)

Keywords

ANEMIA

ANTIVIRAL AGENTS

GLOMERULAR FILTRATION RATE

HEPATITIS C

RIBAVIRIN

TELAPREVIR

Abstract

Background: ANEMIA is more frequent in patients receiving TELAPREVIR with PEGylated interferon/ribavirin (PEG-IFN/RBV) than in those receiving PEG-IFN/RBV alone.Objectives: The objective was to measure the impact of TELAPREVIR on RBV bioavailability and to assess the concomitant renal function.Materials and Methods: Thirty-seven HEPATITIS C virus (HCV) patients non-responders to a previous course of PEG-IFN/RBV therapy and re-treated with triple therapy combining PEG-IFN/RBV and TELAPREVIR were analyzed. RBV bioavailability was measured before the triple therapy initiation, during TELAPREVIR treatment at week (W) 4 and W8, and after TELAPREVIR cessation (post W16). The renal function was assessed by estimating the GLOMERULAR FILTRATION RATE (eGFR).Results: At W4, RBV bioavailability, expressed as mg/L/daily dose/kg body weight, was significantly increased (median increase = 0.06 mg/L/dose/kg; P < 0.001). In parallel, the renal function was impaired with a mean eGFR decrease of -6.8 mL/minutes/1.73 m2 (P = 0.109). Between W4 and W8, RBV bioavailability continued to increase (P < 0.001) but subsequently decreased slightly after TELAPREVIR discontinuation with a concomitant restoration of the renal function (eGFR increase of 6.34 mL/minutes/1.73 m2).Conclusions: Our results indicated a reversible increase in RBV bioavailability after TELAPREVIR exposure, which might be linked to the impairment of the GFR. This also suggests a RBV-telaprevir pharmacological interaction, a possible source of severe ANEMIA observed under triple therapy. These results suggest that RBV pharmacological monitoring may be clinically relevant, especially in the context of first-generation HCV protease inhibitor-based therapy.

Cites

No record.

References

No record.

Cite

APA: Copy

PRADAT, PIERRE, VIRLOGEUX, VICTOR, MAYNARD, MARIANNE, LECLERCQ, MATHILDE, HATU, GIORGIANA, AMIRI, MAJID, LEBOSSE, FANNY, MIAILHES, PATRICK, ZOULIM, FABIEN, GAGNIEU, MARIE CLAUDE, & BAILLY, FRANCOIS. (2015). INCREASED RIBAVIRIN BIOAVAILABILITY ASSOCIATED WITH TELAPREVIR USE IN HEPATITIS C PATIENTS TREATED WITH PEGYLATED -INTERFERON/RIBAVIRIN/TELAPREVIR TRIPLE THERAPY. HEPATITIS MONTHLY, 15(9), 0-0. SID. https://sid.ir/paper/306935/en

Vancouver: Copy

PRADAT PIERRE, VIRLOGEUX VICTOR, MAYNARD MARIANNE, LECLERCQ MATHILDE, HATU GIORGIANA, AMIRI MAJID, LEBOSSE FANNY, MIAILHES PATRICK, ZOULIM FABIEN, GAGNIEU MARIE CLAUDE, BAILLY FRANCOIS. INCREASED RIBAVIRIN BIOAVAILABILITY ASSOCIATED WITH TELAPREVIR USE IN HEPATITIS C PATIENTS TREATED WITH PEGYLATED -INTERFERON/RIBAVIRIN/TELAPREVIR TRIPLE THERAPY. HEPATITIS MONTHLY[Internet]. 2015;15(9):0-0. Available from: https://sid.ir/paper/306935/en

IEEE: Copy

PIERRE PRADAT, VICTOR VIRLOGEUX, MARIANNE MAYNARD, MATHILDE LECLERCQ, GIORGIANA HATU, MAJID AMIRI, FANNY LEBOSSE, PATRICK MIAILHES, FABIEN ZOULIM, MARIE CLAUDE GAGNIEU, and FRANCOIS BAILLY, “INCREASED RIBAVIRIN BIOAVAILABILITY ASSOCIATED WITH TELAPREVIR USE IN HEPATITIS C PATIENTS TREATED WITH PEGYLATED -INTERFERON/RIBAVIRIN/TELAPREVIR TRIPLE THERAPY,” HEPATITIS MONTHLY, vol. 15, no. 9, pp. 0–0, 2015, [Online]. Available: https://sid.ir/paper/306935/en

Related Journal Papers

No record.

Related Seminar Papers

No record.

Related Plans

No record.

Recommended Workshops